- Trials with a EudraCT protocol (213)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
213 result(s) found for: Binding protein.
Displaying page 4 of 11.
| EudraCT Number: 2022-000849-32 | Sponsor Protocol Number: 1/2022 | Start Date*: 2022-05-10 |
| Sponsor Name:Helsinki University Hospital | ||
| Full Title: The effect of tenofovir disoproxil fumarate (TDF) versus tenofovir alafenamide (TAF) on proximal small intestine – a potential mechanism to explain opposing effects on body weight | ||
| Medical condition: HIV-positive people who have good and stable treatment response for HIV-medication which includes either tenofovir disoproxil (TDF) or tenoforvir alafenamide (TAF) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FI (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2006-003425-81 | Sponsor Protocol Number: RLBUHT2763 | Start Date*: 2007-03-29 |
| Sponsor Name:University of Liverpool | ||
| Full Title: Host genetic factors influencing drug disposition and response to HIV treatment | ||
| Medical condition: Pharmacogeneric study of HIV+ patients receiving antiretroviral therapy. We wish to correlate drug concentration with host genetic patients receiving certain HIV drugs. No dosage modification will... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2005-005534-12 | Sponsor Protocol Number: AVH-2004/1 | Start Date*: 2006-04-18 |
| Sponsor Name:The Symbio Herborn Group GmbH | ||
| Full Title: randomized double blind placebo controlled study on the efficacy of autologous autovaccine in house dust mite allergy | ||
| Medical condition: Allergic diseases such as rhinoconjunctivitis or bronchial asthma are a major public health burden. The huge associated costs demand an evidence based therapeutic aproach. The only available causat... | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-004066-19 | Sponsor Protocol Number: CV-NCOV-005 | Start Date*: 2020-12-18 | |||||||||||
| Sponsor Name:CureVac AG | |||||||||||||
| Full Title: COVID-19: A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Clinical Study Evaluating the Safety and Immunogenicity of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adult Health Care ... | |||||||||||||
| Medical condition: Vaccination for prophylaxis of COVID-19 (healthy adults) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-003859-36 | Sponsor Protocol Number: VAC18194RSV2002 | Start Date*: 2019-03-27 | |||||||||||
| Sponsor Name:Janssen Vaccines and Prevention B.V. | |||||||||||||
| Full Title: A Randomized, Controlled, Observer-blind, Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers 12 to 24 Months of Age | |||||||||||||
| Medical condition: Prophylactic respiratory syncytial virus (RSV) | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) FI (Completed) ES (Completed) Outside EU/EEA PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-004070-22 | Sponsor Protocol Number: CV-NCOV-003 | Start Date*: 2021-04-12 | |||||||||||
| Sponsor Name:CureVac AG | |||||||||||||
| Full Title: COVID-19: A Phase 3 multicenter clinical trial to evaluate the safety, reactogenicity and immunogenicity of the investigational SARS-CoV-2 mRNA vaccine CVnCoV in adults 18 years of age and above wi... | |||||||||||||
| Medical condition: Vaccination for prophylaxis of COVID-19 (adults with co morbidities) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-004042-42 | Sponsor Protocol Number: DEER | Start Date*: 2014-06-19 | ||||||||||||||||
| Sponsor Name:King’s College London [...] | ||||||||||||||||||
| Full Title: A study to investigate the potential renoprotective role of sodium-glucose transporter-2 (SGLT-2) antagonist Dapagliflozin in Type 2 diabetic patients with diabetic nephropathy | ||||||||||||||||||
| Medical condition: Diabetic Nephropathy | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2012-000281-38 | Sponsor Protocol Number: LEG-SIL-LTX-05 | Start Date*: 2014-03-25 | |||||||||||
| Sponsor Name:Rottapharm | |||||||||||||
| Full Title: A Randomized, Controlled Study To Investigate The Efficacy, Safety And Pharmacokinetics Of Legalon® Sil, Alone Or In Combination With Ribavirin, For The Prevention Of Recurrent Hepatitis C In Liver... | |||||||||||||
| Medical condition: Recurrent Hepatitis C | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-004105-32 | Sponsor Protocol Number: 307-MET-9002-052 | Start Date*: 2015-04-01 |
| Sponsor Name:Pfizer Inc | ||
| Full Title: Prevention of Retarded Growth by Early Treatment With Recombinant Human Growth Factor (Genotonorm) in Children With Systemic Forms of Chronic Juvenile Arthritis Receiving Long-Term Corticosteroid T... | ||
| Medical condition: Juvenile idiopathic arthritis (JIA) | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2008-002110-22 | Sponsor Protocol Number: LTA-2-2008 | Start Date*: 2008-09-16 | |||||||||||
| Sponsor Name:Prof. dr L.H. van den Berg, UMC-Utrecht | |||||||||||||
| Full Title: A randomised sequential trial of Lithium in amyotrophic lateral sclerosis | |||||||||||||
| Medical condition: Amyotrophic lateral sclerosis (ALS) is a disease characterised by progressive degeneration of motor neurons in brain and spinal cord leading to muscle weakness. ALS can occur at anytime in adulthoo... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-002534-23 | Sponsor Protocol Number: 3124001 | Start Date*: 2018-02-08 | |||||||||||
| Sponsor Name:Orion Corporation Orion Pharma | |||||||||||||
| Full Title: SAFETY AND PHARMACOKINETICS OF ODM-208 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | |||||||||||||
| Medical condition: Metastatic castration-resistant prostate cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: FI (Trial now transitioned) FR (Trial now transitioned) GB (Temporarily Halted) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-003575-11 | Sponsor Protocol Number: VitaminD&TT | Start Date*: 2013-03-05 | |||||||||||
| Sponsor Name:Medizinische Universität Graz, Innere Medizin | |||||||||||||
| Full Title: A randomized, double-blind, placebo controlled trial to evaluate the effects of vitamin D supplementation on androgen levels in hypogonadal men | |||||||||||||
| Medical condition: Male hypogonadism (total testosterone <3ng/ml) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male | ||||||||||||
| Trial protocol: AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-005027-16 | Sponsor Protocol Number: VitDPHPT | Start Date*: 2015-09-24 | |||||||||||
| Sponsor Name:CASA SOLLIEVO DELLA SOFFERENZA IRCCS | |||||||||||||
| Full Title: IMPACT OF VITAMIN D SUPPLEMENTATION ON SKELETAL AND NON SKELETAL MANIFESTATIONS IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM SUBMITTED TO PARATHYROIDECTOMY OR FOLLOWED WITHOUT SURGERY | |||||||||||||
| Medical condition: PRIMARY HYPERPARATHYROIDISM | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-000059-42 | Sponsor Protocol Number: 31/17/0334 | Start Date*: 2018-07-25 | |||||||||||
| Sponsor Name:CHU DE TOULOUSE | |||||||||||||
| Full Title: Comparison of short infusion versus prolonged infusion of ceftolozane-tazobactam among patients with ventilator associated-pneumonia to Pseudomonas aeruginosa in intensive care units | |||||||||||||
| Medical condition: Ventilator associated-pneumonia to Pseudomonas aeruginosa in intensive care units | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-005993-12 | Sponsor Protocol Number: S245.4.012 | Start Date*: 2009-06-18 | |||||||||||
| Sponsor Name:Solvay Pharmaceutical GmbH | |||||||||||||
| Full Title: A three month double-blind, randomized, placebo-controlled, parallel group, multi-center study with Creon® 25.000 MMS? in subjects after an attack of acute pancreatitis suffering from pancreatic ex... | |||||||||||||
| Medical condition: Pancreatic exocrine insufficiency after acute pancreatitis. Insuficiencia pancreática exocrina tras un episodio de pancreatitis aguda. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-000281-15 | Sponsor Protocol Number: mRNA-1273-P204 | Start Date*: 2023-09-19 |
| Sponsor Name:ModernaTX, Inc. | ||
| Full Title: A Phase 2/3, Three-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and ... | ||
| Medical condition: Coronavirus Disease 2019 | ||
| Disease: | ||
| Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2021-000300-38 | Sponsor Protocol Number: 001610 | Start Date*: 2021-02-05 |
| Sponsor Name:Antwerp University Hospital | ||
| Full Title: Vaccination against cOvid-19 In CancER patients under active treatment (Belgium, B-VOICE) | ||
| Medical condition: Onco-hematological patients | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2011-000994-30 | Sponsor Protocol Number: VD1.3 | Start Date*: 2013-02-19 |
| Sponsor Name:Medizinische Universität Graz | ||
| Full Title: A randomized, double‐blind, placebo controlled trial to evaluate the effects of vitamin D supplementation on metabolic and fertility parameters in PCOS women | ||
| Medical condition: Polycystic Ovary Syndrome | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2021-002363-22 | Sponsor Protocol Number: IIV-482 | Start Date*: 2021-05-27 |
| Sponsor Name:National Institute for Public Health and the Environment | ||
| Full Title: Vaccination of older persons against Sars-Cov-2 and cellular immunogenicity for long term protection (participating in the Doetinchem Cohort Study) | ||
| Medical condition: SARS-CoV-19, frailty | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2021-005713-13 | Sponsor Protocol Number: 21102 | Start Date*: 2022-08-16 | |||||||||||
| Sponsor Name:ACELYRIN, INC. | |||||||||||||
| Full Title: A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Moderate to Severe Hidradenitis Suppurativa | |||||||||||||
| Medical condition: Hidradenitis Suppurativa | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) ES (Ongoing) HU (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.